University of Arkansas
Also known as: Allergy/Immunology Department, Arkansas Children's Hospital | Arkansas Cancer Research Center | Arkansas Children's Hospital | Arkansas Childrens Hospital | Arkansas Children's Hospital and University of Arkansas for Medical Sciences | Arkansas Children's Hospital at the University of Arkansas for Medical Sciences | Arkansas Children's Hospital Research Institute | Arkansas Children's Nutrition Center | Arkansas Children's Research Institute | Arkansas Heart Hospital | UAMS | UAMS Center for Addiction Research | UAMS Myeloma Institute for Research and Therapy | UAMS Myeloma Institute for Research & Therapy | UAMS professor | Universitiy of Arkansas for Medical Sciences | University of Arkanas for Medical Sciences website | University of Arkansas | University of Arkansas, Fayetteville | University of Arkansas for Medical Science-Myeloma Institute | University of Arkansas for Medical Sciences / Arkansas Children's Hospital | University of Arkansas for Medical Sciences, Little Rock, AR | University of Arkansas for Medical Sciences/MIRT | University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy | UTMB/University of Arkansas
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2001Last known activity
Apr 1, 2026
Timeline
1870s
- Jan 1, 1871
University of Arkansas— Founded
Drugs by trial phase (96 distinct, 83 trials)
Phase 4 (11 own, 0 via acquisition)
Phase 3 (14 own, 0 via acquisition)
Phase 2 (30 own, 0 via acquisition)
Phase 1 (16 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Asperger Syndrome
- Asphyxia
- Asphyxia Neonatorum
- Atrophy
- Autism Spectrum Disorder
- Autistic Disorder
- Brain Diseases
- Brain Injuries
- Brain Injuries, Traumatic
- Brain Ischemia
- Breast Neoplasms
- Carcinoma in Situ
- Central Nervous System Neoplasms
- Child Development Disorders, Pervasive
- Communicable Diseases
- Cystic Fibrosis
- Disease
- Fibrosis
- Food Hypersensitivity
- Head and Neck Neoplasms
- Heart Septal Defects, Ventricular
- HIV Infections
- Hot Flashes
- Hypersensitivity
- Hypersensitivity, Immediate
- Hypothermia
- Hypoxia-Ischemia, Brain
- Immunologic Deficiency Syndromes
- Infections
- Kidney Diseases
- Kidney Failure, Chronic
- Language Disorders
- Multiple Myeloma
- Myocardial Infarction
- Neoplasms
- Neoplasms, Plasma Cell
- Nervous System Neoplasms
- Papillomavirus Infections
- Peanut Hypersensitivity
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- POEMS Syndrome
- Renal Insufficiency, Chronic
- Sarcoma
- Sarcoma, Kaposi
- Sepsis
- Squamous Intraepithelial Lesions of the Cervix
- Syndrome
- Tobacco Use Disorder
- Wounds and Injuries
Recent trials (50)
- NCT04363034Lead sponsorN/A—
- NCT07029776Lead sponsorPhase 2Apr 1, 2026
- NCT07224009Lead sponsorPhase 2Jan 31, 2026
- NCT06854029CollaboratorPhase 4Nov 30, 2025
- NCT06604065OfficialPhase 1Jul 31, 2025
- NCT06604065Lead sponsorPhase 1Jul 31, 2025
- NCT06313502OfficialPhase 1Jul 19, 2024
- NCT06313502Lead sponsorPhase 1Jul 19, 2024
- NCT06115603Lead sponsorPhase 2Jan 31, 2024
- NCT06055309Lead sponsorPhase 1Jan 31, 2024
- NCT05952934Overall official - principal investigatorPhase 2Jan 31, 2024
- NCT06115603Reponsible party - principal investigatorPhase 2Jan 31, 2024
- NCT05952934Lead sponsorPhase 2Jan 31, 2024
- NCT06055309Overall official - principal investigatorPhase 1Jan 31, 2024
- NCT06115603Overall official - principal investigatorPhase 2Jan 31, 2024
Details
- Founded
- Fayetteville, AR, US Jan 1, 1871
- Last known activity
- Apr 1, 2026